ERBB2 and gastric cancer: Trastuzumab deruxtecan, with significant intracranial efficacy, is now a second-line treatment for HER2-positive gastric cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) [54,58].